Cerebrospinal Fluid Biomarkers and Prediction of Conversion in Patients with Mild Cognitive Impairment: 4-Year Follow-Up in a Routine Clinical Setting

Mild cognitive impairment (MCI) is a very common syndrome in elderly people, with a high risk of conversion to dementia. Several investigations have shown the usefulness of cerebrospinal fluid (CSF) biomarkers (Aβ42, total tau [T-tau], and phosphorylated tau [P-tau]) in predicting the progression to...

Full description

Saved in:
Bibliographic Details
Main Authors: Alessia Lanari, Lucilla Parnetti
Format: Article
Language:English
Published: Wiley 2009-01-01
Series:The Scientific World Journal
Online Access:http://dx.doi.org/10.1100/tsw.2009.106
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832563457831993344
author Alessia Lanari
Lucilla Parnetti
author_facet Alessia Lanari
Lucilla Parnetti
author_sort Alessia Lanari
collection DOAJ
description Mild cognitive impairment (MCI) is a very common syndrome in elderly people, with a high risk of conversion to dementia. Several investigations have shown the usefulness of cerebrospinal fluid (CSF) biomarkers (Aβ42, total tau [T-tau], and phosphorylated tau [P-tau]) in predicting the progression to Alzheimer's disease (AD). We report a 4-year follow-up of MCI patients who underwent CSF evaluation for biomarker assessment, in order to further evaluate the usefulness of CSF analysis in predicting the conversion to dementia in a routine clinical setting. We identified 55 patients with MCI among the consecutive patients, referred from 2001 to 2003 to our Memory Clinic for cognitive disorders, who underwent a complete diagnostic assessment, including lumbar puncture (n = 273). At the end of the follow-up, 31 MCI patients (56%) did not progress to dementia (stable MCI), while 24 (44%) developed a dementia condition. At baseline, the mean levels of CSF Aβ42, T-tau, and P-tau were significantly altered in MCI patients who were converting to dementia with respect to those with stable MCI. All MCI patients with the three altered CSF biomarkers developed dementia within 1 year. Among the stable MCI patients, none showed all three pathological values and only one subject had the pathological value of P-tau. Early diagnosis of dementia and, specifically, a correct prediction of MCI outcome represent a primary goal. To this respect, the role of CSF biomarkers seems to be crucial in a routine clinical setting.
format Article
id doaj-art-d572e13b397040b28e66c201104b81ce
institution Kabale University
issn 1537-744X
language English
publishDate 2009-01-01
publisher Wiley
record_format Article
series The Scientific World Journal
spelling doaj-art-d572e13b397040b28e66c201104b81ce2025-02-03T01:20:15ZengWileyThe Scientific World Journal1537-744X2009-01-01996196610.1100/tsw.2009.106Cerebrospinal Fluid Biomarkers and Prediction of Conversion in Patients with Mild Cognitive Impairment: 4-Year Follow-Up in a Routine Clinical SettingAlessia Lanari0Lucilla Parnetti1Neurology Department, Mantova General Hospital, ItalyCentre for Memory Disturbances, Section of Neurology, University of Perugia, ItalyMild cognitive impairment (MCI) is a very common syndrome in elderly people, with a high risk of conversion to dementia. Several investigations have shown the usefulness of cerebrospinal fluid (CSF) biomarkers (Aβ42, total tau [T-tau], and phosphorylated tau [P-tau]) in predicting the progression to Alzheimer's disease (AD). We report a 4-year follow-up of MCI patients who underwent CSF evaluation for biomarker assessment, in order to further evaluate the usefulness of CSF analysis in predicting the conversion to dementia in a routine clinical setting. We identified 55 patients with MCI among the consecutive patients, referred from 2001 to 2003 to our Memory Clinic for cognitive disorders, who underwent a complete diagnostic assessment, including lumbar puncture (n = 273). At the end of the follow-up, 31 MCI patients (56%) did not progress to dementia (stable MCI), while 24 (44%) developed a dementia condition. At baseline, the mean levels of CSF Aβ42, T-tau, and P-tau were significantly altered in MCI patients who were converting to dementia with respect to those with stable MCI. All MCI patients with the three altered CSF biomarkers developed dementia within 1 year. Among the stable MCI patients, none showed all three pathological values and only one subject had the pathological value of P-tau. Early diagnosis of dementia and, specifically, a correct prediction of MCI outcome represent a primary goal. To this respect, the role of CSF biomarkers seems to be crucial in a routine clinical setting.http://dx.doi.org/10.1100/tsw.2009.106
spellingShingle Alessia Lanari
Lucilla Parnetti
Cerebrospinal Fluid Biomarkers and Prediction of Conversion in Patients with Mild Cognitive Impairment: 4-Year Follow-Up in a Routine Clinical Setting
The Scientific World Journal
title Cerebrospinal Fluid Biomarkers and Prediction of Conversion in Patients with Mild Cognitive Impairment: 4-Year Follow-Up in a Routine Clinical Setting
title_full Cerebrospinal Fluid Biomarkers and Prediction of Conversion in Patients with Mild Cognitive Impairment: 4-Year Follow-Up in a Routine Clinical Setting
title_fullStr Cerebrospinal Fluid Biomarkers and Prediction of Conversion in Patients with Mild Cognitive Impairment: 4-Year Follow-Up in a Routine Clinical Setting
title_full_unstemmed Cerebrospinal Fluid Biomarkers and Prediction of Conversion in Patients with Mild Cognitive Impairment: 4-Year Follow-Up in a Routine Clinical Setting
title_short Cerebrospinal Fluid Biomarkers and Prediction of Conversion in Patients with Mild Cognitive Impairment: 4-Year Follow-Up in a Routine Clinical Setting
title_sort cerebrospinal fluid biomarkers and prediction of conversion in patients with mild cognitive impairment 4 year follow up in a routine clinical setting
url http://dx.doi.org/10.1100/tsw.2009.106
work_keys_str_mv AT alessialanari cerebrospinalfluidbiomarkersandpredictionofconversioninpatientswithmildcognitiveimpairment4yearfollowupinaroutineclinicalsetting
AT lucillaparnetti cerebrospinalfluidbiomarkersandpredictionofconversioninpatientswithmildcognitiveimpairment4yearfollowupinaroutineclinicalsetting